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Pentraxin 3 (PTX3) is a soluble pattern recognition molecule that plays critical roles in 
innate immunity. Its fundamental functions include recognition of microbes, activation of 
complement cascades, and opsonization. The findings that PTX3 is one of the compo-
nent proteins in neutrophil extracellular traps (NETs) and binds with other NET proteins 
imply the importance of PTX3 in the NET-mediated trapping and killing of bacteria. As 
NETs play certain critically important host-protective roles, aberrant NET production 
results in tissue damage. Extracellular histones, the main source of which is considered 
to be NETs, are mediators of septic death due to their cytotoxicity toward endothelial 
cells. PTX3 protects against extracellular histones-mediated cytotoxicity through coag-
gregation. In addition to the anti-bacterial roles performed in coordination with other 
NET proteins, PTX3 appears to mitigate the detrimental effect of over-activated NETs. A 
better understanding of the role of the PTX3 complexes in NETs would be expected to 
lead to new strategies for maintaining a healthy balance between the helpful bactericidal 
and undesirable detrimental activities of NETs.
Keywords: pentraxins, extracellular histones, cytotoxicity, coaggregation, sepsis
iNTRODUCTiON
The innate immune system serves as the first line of defense against pathogen invasion and 
consists of cellular and humoral arm. The innate immune response is triggered by pattern 
recognition molecules (PRMs) upon the recognition of pathogen-associated molecular patterns 
(PAMPs), which are structural patterns conserved across a broad spectrum of microbes (1, 2). 
In addition to PAMPs, PRMs recognize damage-associated molecular patterns (DAMPs) that are 
secreted from damaged cells as a “warning signal from the host” (2). Like the innate immune 
system, PRMs are classified into cellular and humoral components. The cellular arm of PRMs 
includes toll-like receptors (TLRs), C-type lectin receptors (CLRs), scavenger receptors, retinoic 
acid-inducible gene (RIG)-I-like receptors (RLRs) and NOD-like receptors (NLRs) with diverse 
patterns of localization, ligand recognition, and signal transduction. The humoral arm of PRMs 
includes complements, collectines, ficolins, and pentraxins that share a number of fundamental 
mechanisms against infection, such as complement activation, agglutination, neutralization, and 
opsonization (3, 4).
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Pentraxin 3 (PTX3) was the first long pentraxin to be identi-
fied (5). The PTX3 gene is highly conserved across species (6). 
It is a circular multimeric glycoprotein that recognizes certain 
microbes and eliminates them through complement activa-
tion and opsonization. In addition to its activity in the innate 
immune system, PTX3 exerts effects in inflammation and 
matrix regulation (6). PTX3 expression includes hematopoietic 
and stromal cells by means of pro-inflammatory signals, while 
the characteristic expression mode of PTX3 production is that 
neutrophils store PTX3 in granules and release them in a “ready-
to-release” manner (7). It is, thus, not surprising that PTX3 is 
one of the components of neutrophil extracellular traps (NETs) 
in which PTX3 serves as an anti-fungal activity. In addition 
to their host-protective activity, NETs also exert detrimental 
effects against the host. Extracellular histones, the major NET 
components and one of the DAMPs, afford a good example of 
the double-edged sword effect of NET components. They have 
bactericidal activity, but have also been shown to exert a cyto-
toxic effect on endothelial cells in sepsis. PTX3 has an ability to 
attenuate extracellular histone-mediated cytotoxicity through 
coaggregation (8). This implies that the role of PTX3 in NETs is 
not only to combat bacteria but also to mitigate the detrimental 
effects of NETs. Here, we describe our recent findings on the role 
of PTX3 as a regulator of NETs in relation to histone cytotoxicity.
PeNTRAXiN 3: GeNeRAL DeSCRiPTiON 
AND ROLe iN NeTs
Pentraxins
The pentraxins comprise an evolutionarily conserved multim-
eric protein family in which its members share the pentraxin 
domain [~200 amino acids (a.a.) long] in its C-terminal domain 
with a characteristic pentraxin signature (His–x–Cys–x–Ser/
Thr–Trp–x–Ser, where x is any amino acid residue) (6, 9). The 
pentraxins are classified into two subfamilies based upon the 
N-terminal length, i.e., the short pentraxin and long pentraxin. 
C-reactive protein (CRP) and serum amyloid P component (SAP) 
are the prototypical short pentraxins, which are broadly known 
as acute phase proteins (10, 11). Neuronal pentraxin 1 (NPTX1) 
(12), neuronal pentraxin 2 (NPTX2) (13), neuronal pentraxin 
receptor (NPTXR) (14), and PTX4 (15) are the long pentraxins 
that have been reported in addition to PTX3.
General Background of PTX3 (Genome, 
expression, Structure, and Function)
Genome and Expression Pattern
The human PTX3 gene locates on chromosome 3q band 25, and 
consists of three exons and two introns. It consists of 1861 base 
pairs and is translated into 381 amino acids. The first and second 
exons encode the signal peptide (1–17 a.a.) and N-terminal 
domain (18–178 a.a.), and the last and third exon encodes the 
C-terminal pentraxin domain (179–381 a.a.), respectively. The 
promoter region of PTX3 contains PU-1, AP1, NF-κB, SP1, 
and NF-IL6, and the expression of PTX3 is triggered by certain 
primary inflammatory signals, such as TLR agonists, IL-1β, and 
TNFα.PTX3 is expressed several types of cells, including myeloid 
dendritic cells, peripheral blood leukocytes, macrophages, mono-
nuclear phagocytes, vascular endothelial cells, smooth muscle 
cells, fibroblasts, adipocytes, glial cells, cumulus oophorus cells, 
mesangial cells, synovial cells, epithelial cells, and uroepithelial 
cells. Please refer to the cited reviews for the gene structure (3, 9) 
and expression pattern of PTX3 (3, 6) in more detail. In addition 
to the cells described above, lymphatic endothelial cells (16) 
and polymorphonuclear neutrophils (7) have distinct expression 
patterns. The former cells constitutively express PTX3, while the 
latter cells store the PTX3 protein in a “ready-to-release” manner, 
the details of which will be discussed below.
Protein Structure and Ligand Binding
After the processing of its signal sequence, PTX3 protein has an 
N-linked glycosylation of its Asn220 site (17, 18). The glycosidic 
moiety is important for the fine-tuning of the interaction with 
C1q and complement activation (17), the stabilization of Factor H 
binding (19), the interaction with M-ficolin (20), the interaction 
with P-selectin for attenuating neutrophil recruitment at sites of 
inflammation (21), and the blocking of the binding site of the 
influenza virus hemagglutinin (22).
It is considered that, like the case of the short pentraxins, the 
PTX3 C-terminal pentraxin domain forms two antiparallel β 
sheets with a “jellyroll” topology (18, 23). As opposed to the PTX3 
C-terminal domain, which is homologous among the pentraxins, 
the PTX3 N-terminal domain is unrelated to other known pro-
teins. Presta et  al. predicted four α-helix regions connected by 
short loops in the N-terminal domain using the PredictProtein 
server (24). They pointed out a heptad repeat motif (abcdefg) 
spanning a.a. residues 85–91, where a and d are non-polar resi-
dues and e and g are charged residues, together with hydrophobic 
residues repeated with a period of one every three to six a.a. in their 
helical regions (23) (Figure 1A). These motifs confer on PTX3 
N-terminal domain a propensity for forming a coiled-coil struc-
ture. The signal of the α-helix was detected by circular dichroic 
(CD) spectroscopy (8). Inforzato et al. attributed the multimer 
formation of PTX3 to the inter- and intra-molecular disulfide 
bonds in the organization of the matrix (25) and proposed an 
asymmetric octamer structure for PTX3 based on biophysical 
analysis (26). PTX3 forms a circular-tetramer in the N-terminal 
domain, while the C-terminal domain forms octameric structure 
by stacking the two-tetramers. The N-terminal domain of one 
tetramer forms three intra-molecular helical coiled-coils, while 
the other, extended form of the tetramer consists of the inter-
molecular interaction of the α-helixes (Figure  1B). These two 
types of tetramer consist of an octamer structure, thus rendering 
an asymmetry on PTX3. This multimerization is considered to be 
important for the interaction of a variety of PTX3 ligands (27) and 
the recognition of pathogens (28). The anti-PTX3 monoclonal 
antibody MNB4 that recognizes 87–99 a.a. of PTX3 inhibits 
PTX3-inter-alpha-trypsin inhibitor (IαI) interaction (29) and/
or PTX3–FGF2 interaction. The minimal PTX3 N-terminal 
peptide required for interaction with FGF2 is 97–110 a.a. (24) 
(Figure 1B). Tetramer formation is required for FGF2 binding, 
and both types of tetramer can bind to FGF2 (26). We eluci-
dated the tertiary structure of PTX3 by secondary structure 
prediction re-calculated with PSIPRED (30) and SPIDER2 
FiGURe 1 | Predicted molecular structure of PTX3. (A) Amino acid sequence in the PTX3 N-terminus (1–178 a.a.) with the result of secondary structure 
predictions for each residue. H, alpha-helix; E, beta-sheet; C, random coil, respectively. The predictions were carried out using PSIPRED (30) and SPIDER2 (31). 
(B) A molecular modeling of PTX3 based on the result of the secondary structure predictions above as well as earlier studies (23–25, 28, 29). A half of the octamer 
consisting of asymmetric tetramer is shown. SWISS-MODEL (32) built of the pentraxin domain by homology modeling. Red, alpha-helix; light blue, beta-strand; 
yellow, cysteine residue contributes to multimer structure of PTX3; purple, glycosylated asparagine N220 in pentraxin domain; green, Inter-alpha-trypsin inhibitor (IαI) 
binding site, including heptad repeat motif; blue, FGF2 binding site, respectively. The drawing was obtained by USCF Chimera visualization software (33).
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(31) on the basis of the report by Presta et al. (23) (Figure 1A) 
with reference to the quaternary structure analysis reported by 
Inforzato et al. (26) (Figure 1B).
PTX3 in Innate Immunity, Inflammation, and Matrix 
Regulation
Pentraxin 3 exerts effects in the resistance against microbial, 
fungal, and bacterial infections through opsonization via the 
Fcγ receptor, complement regulation, and neutralization by 
direct recognition (3, 34, 35). PTX3 also regulates inflammation 
through complement [the classical complement component 
C1q (36), the alternative complement component Factor H 
(19), Factor H-related protein 5 (37) and C4BP (38), the lectin 
pathway ficolins (20, 39), and mannose-binding lectins (40)] and 
P-selectin interaction (21). Several studies have reported that 
PTX3 participates in the dynamic regulation of matrix formation. 
PTX3 knockout mice display female infertility due to cumulus 
matrix instability (41). The molecular mechanism underlying the 
phenotype is the interaction between PTX3 and the heavy chains 
(HCs) of IαI (29) as well as tumor necrosis factor α-induced 
protein 6 (TNFAIP6, also known as TSG6) (41). IαI and TSG6 
are matrix component proteins that bind to hyaluronan. The 
direct interaction between PTX3 and these proteins builds up the 
super-molecular formation that contributes to proper cumulus 
matrix assembly. The PTX3 N-terminal binding site determined 
for IαI (29) is shown in Figure 1A. In tissue injury models, PTX3 
knockout mice showed excessive fibrin deposition, clotting, 
and increasing collagen deposition (42). Further investigation 
revealed that fibrinogen/fibrin and plasminogen interaction with 
PTX3 promotes fibrinolysis (42). These findings on matrix com-
ponent recognition imply the importance of PTX3 in the regula-
tion of matrix formation as a hub molecule critical for appropriate 
higher-order structure. Interestingly, both the cumulus matrix 
formation and tissue remodeling defects induced by the lack of 
4Daigo et al. PTX3 against Extracellular Histones
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PTX3 were fond to be recapitulated by N-terminal domain PTX3 
(41, 42), and the interaction of fibrinogen/fibrin and plasminogen 
with PTX3 was limited under an acidic condition (42). In con-
trast to the inhibitory activity of SAP in fibrosis, PTX3 promotes 
fibrocyte differentiation through FcγRI in fibrotic lesions (43). 
A detailed at the molecular level of these observations will result 
in a better understanding of matrix formation and the process of 
tissue remodeling supported by PTX3.
Expression and Role of PTX3 in Neutrophils
PTX3 expression is observed in neutrophil precursors but not 
matured neutrophils, while the PTX3 protein can be detected 
in both (7). No PTX3 expression is observed in eosinophils and 
basophils. PTX3 is stored mainly in specific granules, and par-
tially in azurophilic and gelatinase granules (7, 44). In response 
to stimuli, such as microorganisms and TLR agonists, PTX3 is 
released into the extracellular space and localized in NETs. NETs 
comprise a mesh-like structure that consists mainly of DNA and 
histones (45). Some of the proteins derived from neutrophils are 
localized in NETs and are active in the trapping and killing of 
bacteria (46, 47). The PTX3 in NETs co-localizes with microor-
ganisms and other NET component proteins (7, 44, 48). As it is 
expected that the complex formation of PTX3 with other proteins 
in NETs exerts synergistic antimicrobial effects, further investiga-
tion will be needed to fully understand the activities of the NET 
component proteins.
CYTOTOXiC eFFeCT OF 
eXTRACeLLULAR HiSTONeS ON THe 
eNDOTHeLiUM iN SePSiS
The extracellular Histones: A Double-edged 
Sword in NeTs
Histones are highly basic proteins that bind to DNA in the 
nucleus. Nuclear DNA becomes tightly condensed with the help 
of histones and ultimately forms chromosomes. Histones consist 
of five classes; H2A, H2B, H3, and H4 are the core histones, 
while H1 and H5 are linker histones (49). As well as the crucial 
functions of histones in the intracellular space, the extracellular 
histones also play certain roles, especially of the toxic sort. The 
first extracellular role of histones to be reported was that they are 
toxic to microbes (50). The toxic activity of purified calf thymus 
histones against various types of microorganisms was reported, 
including Escherichia coli K-12, Klebsiella pneumoniae and strains 
of Shigdlae, Salmonella typhimurium, and Pseudomonas. The 
microbicidal effect of each member of the histones was reported 
by subsequently. Histone H4 was identified from human sebocyte 
extract as an antimicrobial protein candidate and was shown to 
exert antimicrobial activity against Staphylococcus aureus and 
Propionibacterium acnes (51). The histones H2A and H2B exert 
a lethal effect on Leishmania amazonensis, but histone H1 does 
not exert any leishmanicidal effect (52). However, in contrast 
to the report by Wang et al., histone H1 has been identified as 
a potential antimicrobial agent (53). Although as yet not fully 
described, these reports imply that histone members have differ-
ent types of toxic activities against a variety of microorganisms.
In contrast to the host-defense role of the extracellular 
histones, only detrimental effects have been reported to date. 
Extracellular histones are also toxic to host cells (54). The cyto-
toxicity of extracellular histones toward a variety of cell types 
and organs has been reported (55). Similar to the toxic effect 
against microbes, different histone members-dependent toxic-
ity to each cell type has been reported. In the case of histone-
mediated cytotoxicity to endothelial cells, histone H3 and H4 are 
the major components involved (56). As opposed to endothelial 
cells, histone H1 exerts cytotoxic effect against leukemia cells 
by causing severe plasma membrane damage while it does not 
affect normal peripheral blood mononuclear cells and bone mar-
row cells (57), suggesting that histone H1 exerts its cytotoxicity 
through leukemia cell-specific membrane components. In line 
with the report by Class et al., only histone H1, not core histones, 
is toxic to cortical neurons (58). In accordance with the reports 
above, the contribution of extracellular histones to certain dis-
ease models [reviewed by Allam and colleagues (55)] is mostly 
related to tissue injury.
In addition to the toxic effect of extracellular histones, signaling 
pathway activation and platelet aggregation have been reported. 
In sterile inflammation and cellular injury models, extracellular 
histones are released, and these are protected by an anti-histone 
antibody or as observed in TLR2- and TLR4-knockout mice (59), 
suggesting that TLR2 and TLR4 act as extracellular histone recep-
tors. Similarly, the extracellular histone–TLR9–MyD88 pathway 
has been also reported in a hepatic ischemia/reperfusion injury 
model (60), as shown by the inhibitory effect of an anti-histone 
antibody and as observed in TLR9- and MyD88-knockout mice. 
Additionally, histone-mediated NLRP3 inflammasome activation 
has been confirmed both in vitro and in vivo (61). Extracellular 
histones bind to platelets and induce platelet aggregation. Histones 
activate platelets, and the TLR2 and TLR4 pathways are involved 
(62). Histone induces platelet aggregation, some part of which 
is mediated through fibrinogen and αIIβ3-integlin. Interestingly, 
similar to the cytotoxic effect, histone H3 and H4 display higher 
levels of platelet activation and aggregation. Consistent with the 
reports above, an in vivo analysis revealed that histone infusion 
resulted in thrombocytopenia (63).
Considering the fact that histones are the most abundant 
NET components (46), the histones in NETs would be expected 
to exert a lethal effect on the microbes captured. In sepsis, NETs 
prevent the dissemination of microbes in order to be able to 
capture them (64). However, growing evidence suggests that 
NETs also inflict tissue damage. Indeed, NETs contribute to the 
pathogenesis of a number of diseases (65, 66), including sepsis 
(65, 67). Histone blockade has been shown to be effective in pro-
tecting against histone-delivered/histone-mediated cytotoxic 
effect (68) and in an acute lung injury model in which NETs 
contribute (69).
Relevance of the extracellular Histones 
to Sepsis
Sepsis is a life-threatening organ dysfunction caused by a dys-
regulated host response to infection (70–72). The innate immune 
response participates in the pathogenesis of sepsis. In the 
TABLe 1 | inhibitors of extracellular histones.
inhibitors inhibitory effects on the pathogenic effects of extracellular histones Reference
endothelium cytotoxicity Platelet aggregation Thrombocytopenia Lung injury Acute death
APC Inhibit – – Inhibit Inhibit (56)
Heparin Inhibit Inhibit Inhibit Inhibit Inhibit (63, 79)
Albumin Inhibit Inhibit – – – (80, 81)
CRP Inhibit Inhibit Inhibit Inhibit Inhibit (82)
rTM – Inhibit Inhibit Inhibit Inhibit (83)
IαI Inhibit Inhibit Inhibit Inhibit – (84)
PTX3 Inhibit – No inhibitory effect Inhibit Inhibit (8, 81)
APC, activated protein C; CRP, c-reactive protein; rTM, recombinant thrombomodullin; IαI, inter-alpha-trypsin inhibitor; PTX3, pentraxin.3.
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initiation of sepsis, PRMs recognize the PAMPs that are derived 
from invading microorganisms. Upon PAMP recognition, PRM 
signal transduction triggers the secretion of pro-inflammatory 
mediators from innate immune cells (73–75). On the progression 
of sepsis, the innate immune system becomes over-reactive. This 
leads to hypercytokinemia and the recruitment of neutrophils 
into infectious regions, eventually resulting in multi-organ failure 
(75). In addition to PAMPs, DAMPs contribute to the pathogen-
esis of sepsis (73). DAMPs also trigger PRM-mediated signaling 
in systemic inflammatory response syndrome (SIRS), including 
trauma, burns, ischemia, and hemorrhage (73, 74, 76). As one 
of the DAMPs, the extracellular histone-mediated cytotoxicity 
toward endothelial cells has emerged as one of the features of the 
pathogenesis of sepsis (55, 56). Extracellular histones are present 
in the plasma of patients with sepsis (77). Histone administration 
in  vivo results in neutrophil margination, vacuolated endothe-
lium, intra-alveolar hemorrhage, and macro- and micro-vascular 
thrombosis, all of which are similar to the events that take place 
in the pathogenesis of sepsis (56).
PROTeCTive ROLe OF PTX3 AGAiNST 
eXTRACeLLULAR HiSTONeS: 
iMPLiCATiONS FOR THe MAiNTeNANCe 
OF A GOOD BALANCe OF NeTs
Extracellular histones are considered as a major factor in the 
severity of sepsis that results in organ failure and, thus, are 
targets in the treatment of sepsis. Certain inhibitors of the 
extracellular histone-mediated detrimental effects have been 
reported, such as activated protein C (APC), heparin, albumin, 
CRP, recombinant thrombomodullin (rTM), and IαI. The inhibi-
tory effect against extracellular histones differs for each factor 
(Table 1). Extracellular histones were identified in a proteomic 
analysis of circulating PTX3 complexes in patients with sepsis 
(48). Considering the report that PTX3-transgenic mice are 
resistant to death from sepsis (78), the complex formation of 
PTX3 and histones is considered to have a host-protective in 
sepsis by attenuating extracellular histone-mediated detrimental 
effects. In the effort to understand the molecular mechanisms of 
PTX3–histone complex formation, both direct and high-affinity 
binding between PTX3 and histones has been reported. Of note, 
it was found that the binding induced coaggregation of PTX3 
with histones due to a disorder of the PTX3 secondary structure 
(Figures 2A,B) (8). A cell-based assay revealed that PTX3 blocks 
histone-mediated cytotoxic activity toward endothelial cells. 
This blockade induced by PTX3 has been confirmed in all of the 
histone members. An in vivo analysis performed to investigate the 
function of PTX3–histone complex formation showed that PTX3 
protects against histone-mediated endothelial cell cytotoxicity. 
The N-terminal domain of PTX3 was shown to be sufficient for 
both aggregate formation with histones and protection against 
histone cytotoxicity. This suggests the possibility of using the 
N-terminal PTX3 domain protein in sepsis treatment; indeed, 
in  vivo administration resulted in resistance to septic lethality. 
Interestingly, however, the in vivo administration of PTX3 attenu-
ated extracellular histones-mediated cytotoxicity, but did not sup-
press histone-mediated thrombocytopenia (Figures 2C,D). This 
result suggests that PTX3 has a distinct protective mechanism 
against histone-mediated detrimental effects because, among the 
factors reported, PTX3 is the only molecule that does not also 
protect against thrombocytopenia (Table 1). As it is considered 
that NETs are the source of extracellular histones, the protec-
tive activity of PTX3 against histone-mediated endothelial cell 
cytotoxicity implies that PTX3 participates in the regulation of 
NETs by attenuating the detrimental effects of NETs exerted by 
extracellular histones (Figure 3).
PeRSPeCTiveS AND CONCLUDiNG 
ReMARKS
Pentraxin 3 in NETs plays a variety of antimicrobial roles through 
pathogen recognition, complement regulation, and complex for-
mation with other NET component proteins, including histones. 
Growing evidence supports the notion that PTX3 has a role in 
the regulation of extracellular histones, which are considered 
to be both diagnostic and therapeutic targets in certain severe 
diseases, including sepsis, due to their cytotoxicity and DAMP 
activity. PTX3 exerts a host-protective role against the histone-
mediated detrimental effects that occur in sepsis. It is also 
expected that an elucidation of the detail of PTX3–histone aggre-
gate formation will lead to new strategies for sepsis treatment. 
It is noteworthy that the matrix formation, tissue remodeling 
and aggregate formation induced by PTX3 are mainly associated 
with the N-terminal domain of PTX3. The N-terminal domain 
FiGURe 3 | Schematic illustration of the roles of PTX3 in NeTs. The PTX3 present in NETs forms a complex with other NET component proteins, including 
bactericidal proteins. This might enhance microbial clearance via synergistic effects. NET histones exert cytotoxicity toward endothelial cells, but PTX3 attenuates 
this cytotoxicity through aggregation. Thus, PTX3 function to maintain the balance of the beneficial and detrimental effects of neutrophils.
FiGURe 2 | Roles of PTX3 against extracellular histones. (A) Electron microscopic image of PTX3–histones coaggregation. Scale bar: 0.2 μm. (B) CD spectra 
of PTX3–histone mixture. (C) In vivo protective effect of PTX3 administration against histone infusion-mediated hemorrhage in the murine lung. (D) Histone 
infusion-mediated thrombocytopenia was not rescued by PTX3 administration. All of the results were obtained from the paper by Daigo et al. (8).
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of PTX3 has the capacity to form a coiled-coil structure through 
heptad repeat motif with repeated hydrophobic residues. As a 
result of its activity of inter-molecular disulfide bond formation, 
PTX3 forms large complexes that interact with many different 
proteins. Such super-molecular formation with the assistance of 
PTX3 might be the ancestor of host-protective reactions. Further 
investigations are needed to elucidate the molecular mechanism 
of PTX3 complex interactions with proteins in NETs, especially 
histones.
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